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Summary
 
The Jak family tyrosine kinase, Jak3, is involved in signaling through cytokine receptors that
utilize the common 
 
g
 
 chain (
 
g
 
c
 
), such as those for IL-2, IL-4, IL-7, IL-9, and IL-15. Recent
studies of Jak3-deficient mice and humans have demonstrated that Jak3 plays a critical role in B
and T lymphocyte maturation and function. The T lymphocyte defects in Jak3-deficient mice
include a small thymus, a decrease in peripheral CD8
 
1
 
 cells, an increase in the surface expres-
sion of activation markers, and a severe reduction in proliferative and cytokine secretion re-
sponses to mitogenic stimuli. To determine whether the peripheral T lymphocyte defects result
from aberrant maturation in the thymus or from the absence of Jak3 protein in peripheral T cells,
we generated reconstituted mice that express normal levels of Jak3 protein in the thymus but
lose Jak3 expression in peripheral T cells. Jak3 expression in the thymus restores normal T cell
development, including CD8
 
1
 
, 
 
gd
 
, and natural killer cells. However, the loss of Jak3 protein in
peripheral T cells leads to the 
 
Jak3
 
2
 
/
 
2
 
 phenotype, demonstrating that Jak3 is constitutively re-
quired to maintain T cell function.
 
T
 
 lymphocyte maturation and function are regulated by
a number of signal transduction pathways. During T cell
development in the thymus, the progressive maturation of
T cells in large part is mediated by the TCR. First, the pre-
TCR is required to induce the differentiation of CD4
 
2
 
CD8
 
2
 
 into CD4
 
1
 
CD8
 
1
 
 thymocytes and their subsequent
expansion (1); at the CD4
 
1
 
CD8
 
1
 
 stage, the mature 
 
ab
 
TCR is required to mediate both positive and negative se-
lection of the TCR repertoire, as well as CD4 versus CD8
lineage commitment (for review see reference 2). In addi-
tion to the TCR, signals induced by interactions of thy-
mocytes with thymic stromal cells are critical for T cell
maturation (3), as are signaling pathways induced by solu-
ble growth factors or cytokines (4, 5). Once T cells are ma-
ture, their ability to function properly is again dependent
on a number of different signaling pathways. Most notably,
T cell responses are contingent on an intact TCR signaling
pathway involving molecules such as Zap-70 (6–8), Lck
(9), Fyn (10, 11), and Vav (12–14). Until recently, signifi-
cantly less was known about the role of other signaling
pathways, such as those initiated by costimulatory mole-
cules or cytokines, in the maintenance of a functional and
responsive immune system.
Recent studies utilizing gene targeting in mice have re-
vealed the importance of the B7 ligand, CTLA-4, and the
IL-2 signaling pathway in preserving the balance between
resting and activated T cells. For instance, loss of expression
of the costimulatory molecule CTLA-4 (15, 16), or of the
 
a
 
 (17) or 
 
b
 
 (18) chain of the IL-2 receptor, results in dra-
matic imbalances in T cell function, leading to accumula-
tion of activated T cells and, in two of the cases, to lympho-
cyte infiltration into many organs and premature death of
the animals. In contrast with this, mice and humans lacking
the IL-2 receptor 
 
g
 
 chain (
 
g
 
c
 
)
 
1
 
 (19–21), or the 
 
g
 
c
 
-associated
signaling protein, Jak3 (22–26), have severe combined im-
munodeficiency (SCID), with defects in lymphocyte matu-
ration as well as function. The extremely severe phenotype
of 
 
g
 
c
 
-deficient and Jak3-deficient individuals is due to the
fact that 
 
g
 
c
 
 is also a component of the receptors for IL-4,
IL-7, IL-9, and IL-15 (27–31); thus, individuals deficient in
 
g
 
c
 
 or Jak3 have pleiotropic defects resulting from the loss of
multiple cytokine signaling pathways. Therefore, it has
been impossible to assess the role of 
 
g
 
c
 
 or Jak3 in mature
peripheral T cell function, as a consequence of the fact that
T cell development is defective in the absence of each of
these important proteins.
Recently, we and others have generated mice lacking ex-
pression of the 
 
g
 
c
 
-associated signaling protein, Jak3 (24–26).
The phenotype of these mice strongly resembles that seen
in 
 
g
 
c
 
-deficient mice (19, 20). For instance, both B and T cell
development is aberrant in Jak3 mutant mice. In the bone
marrow, B cell maturation is blocked at the pre-B stage, re-
sulting in few IgM
 
1
 
 B cells in adult Jak3-negative mice. In
the thymus, Jak3-deficient mice have an unusual defect in
 
1
 
Abbreviations used in this paper:
 
 
 
g
 
c
 
, IL-2 receptor 
 
g
 
 chain; XCID, moder-
ate combined immunodeficiency disease.
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T cell development. The thymi of the mice are extremely
small (
 
z
 
1–10% of normal); yet, T cell maturation appears
to progress relatively normally. In spite of these small
thymi, adult 
 
Jak3
 
2
 
/
 
2
 
 mice have nearly normal numbers of
CD4
 
1
 
 (but not CD8
 
1
 
) T cells in their spleens (24–26), al-
though the 
 
Jak3
 
2
 
/
 
2
 
 peripheral T cells are phenotypically
and functionally abnormal (26). By surface phenotype, vir-
tually all of the 
 
Jak3
 
2
 
/
 
2
 
 T cells resemble activated or mem-
ory cells, rather than naive, resting cells. Functionally, the
 
Jak3
 
2
 
/
 
2
 
 T cells fail to proliferate in response to mitogenic
stimuli. The most unexpected finding was the severe defi-
ciency in IL-2 secretion by 
 
Jak3
 
2
 
/
 
2
 
 T cells stimulated
through their TCR plus CD28 (26).
These data provide an interesting contrast to the pheno-
type of T cells in mice lacking other components of the IL-2
signaling pathway, such as IL-2 itself, or the IL-2 receptor
 
a
 
 or 
 
b
 
 chains (17, 18, 32). Instead of being hyper activated
and prone to causing autoimmune syndromes, 
 
Jak3
 
2
 
/
 
2
 
 T cells
appear anergic (26). From our initial studies, the reason for
the loss of T cell function in the Jak3-deficient mice was
unclear. Since T cells in these mutant mice lack Jak3 pro-
tein at all stages of development, it was impossible to distin-
guish defects due solely to the absence of Jak3 in mature
T cells from defects acquired earlier during T cell matura-
tion. Specifically, aberrant T cell development in the thy-
mus might be responsible for the abnormal phenotype and
responsiveness of the peripheral 
 
Jak3
 
2
 
/
 
2
 
 T cells. Alterna-
tively, T cells might be functionally normal as they de-
velop, and may acquire the unresponsive phenotype due to
the absence of specific cytokine receptor signals as mature
T cells. To address this issue, we have reconstituted Jak3-
deficient mice with wild type Jak3 under conditions in
which Jak3 is expressed in thymocytes and then lost from
peripheral T cells. These studies demonstrate that all phe-
notypic and functional defects of 
 
Jak3
 
2
 
/
 
2
 
 T cells result
from the absence or decreased expression of Jak3 in mature
peripheral T cells.
 
Materials and Methods
 
Transgenic Mice and Southern Blot Analysis.
 
Both wild-type and ki-
nase-dead 
 
Jak3
 
 cDNAs (33) were introduced into the Lck proxi-
mal promoter vector (34), a gift from R. Perlmutter. Lck–
 
Jak3
 
sequences were removed from the bacterial vector DNA by
cleavage with NotI, and prepared for microinjection. DNA was
injected into (C57Bl/6 
 
3
 
 C3H)F
 
2
 
 fertilized eggs by standard pro-
cedures (35). Pups were screened for the transgene by Southern
blot analysis of EcoRI digested tail DNA probed with an 0.35-kb
EcoRI-HindIII fragment of the 
 
Jak3
 
 cDNA clone. Founders were
backcrossed to C57Bl/10 mice; transgenic progeny were then
crossed to 
 
Jak3
 
2
 
/
 
2
 
 mice to generate homozygous 
 
Jak3
 
-deficient
mice heterozygous for each Lck–
 
Jak3
 
 transgene.
 
Western Blot Analyses.
 
Lysates from individual thymi or spleens
were prepared by generating a cell suspension, counting the cells,
and lysing them at 10
 
8
 
/ml in buffer containing 1% Triton X-100.
Jak3 was immune precipitated from lysate of 1 
 
3
 
 10
 
7
 
 thymocyte–
cell equivalents or 2 
 
3
 
 10
 
7
 
 splenocyte–cell equivalents with an
anti-Jak3 monoclonal antibody specific to the carboxy-terminal
25 amino acids of murine Jak3 (33). Washed immune precipitates
were fractionated by SDS-PAGE, transferred to nylon mem-
branes, and probed with an anti-Jak3 rabbit antiserum, as de-
scribed previously (26).
 
Flow Cytometry Analysis.
 
Bone marrow, thymocyte, and sple-
nocyte cell suspensions were prepared and counted for total cellular-
ity. For flow cytometry, 5 
 
3
 
 10
 
5
 
 cells were stained with directly
conjugated antibodies to CD45R (B220), CD4, CD8 (GIBCO-
BRL, Gaithersburg, MD) or biotinylated anti-IgM (PharMingen)
and streptavidin–Cy-Chrome (PharMingen, San Diego, CA). For
activation marker analyses, 5 
 
3
 
 10
 
5
 
 splenocytes were stained with
antibodies to CD4, CD8 (GIBCO-BRL), and biotinylated anti-
CD44 (PharMingen) or biotinylated anti-CD62L (MEL-14) (Phar-
Mingen), followed by streptavidin–FITC (PharMingen or South-
ern Biotech, Birmingham, AL).
 
Intracellular IL-2 Assays.
 
5 
 
3
 
 10
 
5
 
 splenocytes were plated in
96-well microtiter plates previously coated with goat anti–ham-
ster antibody (5 
 
m
 
g/ml) followed by anti-CD3 antibody (5 
 
m
 
g/ml),
and cultured for 5 h in the presence of a 1/8 dilution of anti-
CD28 antibody hybridoma supernatant (determined to be satu-
rating by cell surface staining). As a control, cells were cultured in
media alone. To inhibit secretion of newly synthesized IL-2,
stimulations were carried out in the presence of 10 
 
m
 
M mon-
ensin and 5 
 
m
 
g/ml brefeldin A (Sigma Chemical Co., St. Louis,
MO). After stimulation, the cells from 4 wells were pooled and
stained with PE-conjugated anti-CD4 antibody and biotinylated
anti-CD44 antibodies followed by streptavidin–Cy-Chrome (Phar-
Mingen). Antibody stains were carried out in staining buffer con-
taining 10 
 
m
 
M monensin. Cells were fixed in 4% paraformaldehyde
for 20 min on ice, washed, and permeabilized with 0.5% saponin
(Sigma) in PBS, 1% BSA, 0.05% NaN
 
3
 
. Cells were then stained
with FITC-conjugated anti-IL-2 antibody (PharMingen) for 30
min on ice, washed twice with 0.5% saponin buffer, and analyzed
by flow cytometry.
 
T Cell Functional Assays.
 
T cells were stimulated by culturing
in wells coated with goat anti–hamster antibody followed by anti-
CD3 antibody, in the presence of anti-CD28 antibody hybridoma
supernatant as described above. As a control, cells were cultured
in media alone. For proliferation assays, 1 
 
3
 
 10
 
5
 
 total thymocytes
or total splenocytes adjusted to contain 1 
 
3
 
 10
 
4
 
 CD4
 
1
 
 T cells per
well were cultured for 48 h, then pulsed overnight with [
 
3
 
H]thy-
midine and counted. For cytokine assays, 1 
 
3
 
 10
 
6
 
 total thymo-
cytes or total splenocytes adjusted to contain 1 
 
3
 
 10
 
5
 
 CD4
 
1
 
 T cells
per well were stimulated. Supernatants from duplicate cultures
were harvested at 24 h, and IL-2 and IL-3 levels were quantitated
by titration on indicator cells. For IL-2, 1 U/ml corresponds to
1/50 maximal proliferation of the HT-2 indicator cells (Fig. 4 
 
A
 
)
or 1/10 maximal proliferation of the indicator cells (Fig. 4 
 
B
 
). For
IL-3, 1 U/ml corresponds to 1/10 maximal proliferation of the
DA-1 indicator cells.
 
Results and Discussion
 
We considered two possible explanations for the pheno-
typic and functional defects in peripheral 
 
Jak3
 
2
 
/
 
2
 
 T cells.
First, 
 
Jak3
 
2
 
/
 
2
 
 T cells might be abnormal due to defects re-
sulting from aberrant T cell development in the thymus; al-
ternatively, 
 
Jak3
 
2
 
/
 
2
 
 T cells might be functionally and phe-
notypically normal when they leave the thymus, and might
acquire their defects due to the absence of Jak3 in the pe-
riphery. To investigate the stage of development at which
 
Jak3
 
2
 
/
 
2
 
 T cells acquired their phenotypic and functional
defects, we utilized a transgenic reconstitution system. The 
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wild-type Jak3 cDNA (33) was placed under control of the
Lck proximal promoter (34). This vector has been used in
numerous transgenic lines to express both cell surface and
signal transduction proteins in thymocytes; in some cases,
the transgene-encoded protein is also expressed in periph-
eral T cells, and in other cases, transgene expression is re-
stricted to thymocytes (36–42). One of our transgenic lines
expressed the Jak3 protein in both thymocytes and periph-
eral T cells, and therefore can serve as a positive control
(hereafter referred to as tgthy1spl). A second line was also
identified in which Jak3 was expressed in thymocytes, but
was lost in peripheral cells over time (hereafter referred to
as tgthy).
Both transgenic lines were crossed to the Jak32/2 mice,
to generate mice homozygous for the Jak3 mutation and
heterozygous for one of the transgenes (Fig. 1 A). Analysis
of Jak3 protein levels indicated that both transgenic lines
expressed substantial amounts of Jak3 in thymocytes, while
only the Jak32/2 (tgthy1spl) line expressed levels of Jak3 com-
parable to wild type in the spleen (Fig. 1 B). In the Jak32/2
(tgthy) line, Jak3 protein is barely detectable in spleen cells
of a very young mouse (25 d) and becomes undetectable in
older mice (Fig. 1 B and C); in contrast, no decrease in the
levels of Jak3 protein was observed in the spleens of Jak32/2
(tgthy1spl) mice up to 120 d of age (Fig. 1 D). These findings
strongly suggest that Jak3 is constitutively expressed in pe-
ripheral T cells in the Jak32/2 (tgthy1spl) mice, as the major-
ity of T cells in a 4-mo-old mouse are not recent thymic
emigrants, but cells that have been out of the thymus for
several months. In contrast, the loss of detectable Jak3 pro-
tein from the spleen cells of older Jak32/2 (tgthy) mice sug-
gests that, in this transgenic line, the peripheral Jak3 protein
observed in young animals is the residue of thymic Jak3 ex-
pression. However, we cannot rule out the possibility that
the difference in detectable Jak3 expression between these
two transgenic lines results from a difference in the dose of
expression of the transgenes.
As a negative control, Jak32/2 mice were also reconsti-
tuted with a kinase-dead Jak3 construct driven by the Lck
proximal promoter (hereafter referred to as tgkd) (Fig. 1 D).
For these experiments, we utilized a Jak3 cDNA carrying
a mutation in the codon for the conserved lysine residue
present in all protein kinase domains (43). Substitution of
Arg for Lys at this position (residue 851) eliminates all de-
tectable tyrosine kinase activity of Jak3 (33). The kinase-
dead Jak3 protein was expressed in both thymocytes and
peripheral T cells at levels comparable to those found in the
Jak31/2 control (Fig. 1 D).
Figure 1. Reconstituted ex-
pression of Jak3 in Jak32/2 mice
with Lck–Jak3 transgenes. (A)
Southern blot of EcoRI-digested
tail DNA from mouse pups indi-
cating the genotyping of the en-
dogenous  Jak3 locus (Jak31/2,
lanes 1, 2, 4; and Jak32/2, lanes 3
and 5), as well as the wild-type
Jak3 transgenes (tgthy1spl, lanes 3
and 4; and tgthy, lanes 1 and 5).
The blot was probed with an
0.35-kb EcoRI–HindIII frag-
ment of the Jak3 cDNA clone
(33). (B, C, D) Protein immuno-
blots of Jak3 immunoprecipi-
tates from thymocytes and sple-
nocytes of the indicated mice.
Lysates were from Jak32/2
(tgthy1spl) and Jak32/2 (tgthy) mice
at 25 d of age (B) or 33 d of age
(C). In (D), lysates were from a
Jak32/2 (tgthy1spl) mouse at 120 d
of age and a Jak32/2 (tgkd) mouse
at 49 days of age. Jak3 was im-
munoprecipitated using an anti-
Jak3 monoclonal antibody (33)
from lysate of 1 3 107 thy-
mocytes or 2 3 107 splenocytes.
The membranes were probed with
anti-Jak3 rabbit antiserum (26).200 Peripheral Expression of Jak3 Maintains T Cell Function
Jak32/2 (tgthy1spl), Jak32/2 (tgthy), and Jak32/2 (tgkd) mice
were analyzed to determine the reconstitution of both the
B and T cell lineages. Flow cytometry analysis of bone
marrow cells indicated that no reconstitution of B cell de-
velopment had occurred in any of these lines, as assessed by
the lack of CD45R (B220)1 IgM1 cells (Fig. 2 A). Staining
of bone marrow cells with antibodies to CD43 and CD45R
(B220) also indicated that the block in B cell development
observed in the Jak32/2 mice is not corrected with any of
the Lck promoter–driven Jak3 transgenes (data not shown).
Analysis of B cells in the spleen demonstrated a reduced
level of CD45R (B220)1 IgM1 cells in the Jak32/2 mice ex-
pressing either wild-type or kinase-dead Jak3 transgenes
compared with the Jak31/2 control (Fig. 2 A).
Both transgenic lines expressing wild type Jak3 in the
thymus were capable of completely reconstituting the de-
fects in T cell maturation. Thymi from Jak32/2 (tgthy1spl)
and Jak32/2 (tgthy) mice were reconstituted to the normal
number of cells (Fig. 2 B). In addition, the increased CD41/
CD81 ratio often observed in the thymi of Jak32/2 mice
was not observed in thymuses of either line of Jak32/2
mice reconstituted with wild-type Jak3. Staining of spleen
cells from the Jak32/2 (tgthy1spl) and Jak32/2(tgthy) mice also
demonstrated the recovery of normal T cell maturation
Figure 2. Both wild-type Jak3
transgenes reconstitute T cell,
but not B cell, development in
Jak32/2 mice. (A) The bone
marrow, thymus, and spleen cells
of  Jak31/2,  Jak32/2,  Jak32/2
(tgkd), and 35-d-old Jak32/2
(tgthy1spl) and Jak32/2 (tgthy) mice
were stained with the indicated
antibodies and analyzed by flow
cytometry. Staining is shown on
a logarithmic scale of fluores-
cence intensity. Numbers in the
quadrants indicate subpopula-
tion percentages. The dot plots
are representative of average
staining profiles, although some
Jak32/2 individuals had greatly
increased CD41/CD81 ratios in
the thymus and spleen. (B) The
total cellularity of bone marrow,
thymus, and spleen of mice ana-
lyzed in these experiments is in-
dicated. For each organ, Jak31/2,
lane 1; Jak32/2, lane 2; Jak32/2
(tgthy1spl), lane 3; Jak32/2 (tgthy),
lane 4; and Jak32/2 (tgkd), lane 5
are shown. Note the reconstitu-
tion of normal thymocyte cellu-
larity by both wild-type, but not
the kinase-dead, Jak3 transgenes.
Data shown are representative of
greater than six independent ex-
periments.201 Thomis and Berg
(Fig. 2 A). In particular, the Jak32/2 mice generally lack
peripheral CD81 T cells, a defect that is corrected in both
of these reconstituted lines. In contrast, the kinase-dead
Jak3 could not reconstitute thymus cellularity or CD81 cell
development (Fig. 2 A and B). Another feature of the
Jak32/2 mice is that they lack gd T cells and NK cells (25);
in addition, peripheral lymph nodes are nearly undetectable
(24-26). The Jak32/2 mice reconstituted with wild type
Jak3 have normal numbers of CD42CD82 gd TCR1 cells in
their thymus and normal numbers of CD42TCR2NK1.11
cells in their spleen; however, they still lack lymph nodes
(data not shown).
The reconstituted Jak32/2 mice were examined for the
surface phenotype and function of their T cells. Splenic
T cells were stained with antibodies to CD4, CD8, and a
panel of activation markers. Analysis of CD44 and CD62L
(MEL-14) levels on gated CD41 T cells indicate that Jak32/2
T cells resemble activated or memory T cells, expressing
high levels of CD44 and low levels of CD62L (Fig. 3). The
T cells in the Jak32/2 (tgthy1spl) mice are completely re-
stored to normal, appearing indistinguishable from control
(Jak31/2) T cells at all ages analyzed (Fig. 3; data not shown).
In contrast, the splenic CD41 T cells from the Jak32/2
(tgkd) mice are indistinguishable from Jak32/2 T cells (Fig.
3). Most interestingly, CD41 T cells from Jak32/2 (tgthy)
mice have a cell surface phenotype that appears to correlate
with peripheral Jak3 protein expression (Fig. 3). In the
youngest  Jak32/2 (tgthy) mouse shown (25 d of age), where
Jak3 protein is still detectable in the spleen (see Fig. 1 B),
the majority of CD41 T cells are CD44lo and CD62Lhi. In
an older mouse (35 d of age), where Jak3 protein is no
longer detectable in the spleen (see Fig. 1 C), two popula-
tions of T cells can be seen. In an even older mouse (42 d
of age), most of the T cells in the Jak32/2 (tgthy) mouse are
CD44hi and CD62Llo, and resemble the Jak32/2 T cells.
This gradual appearance of phenotypically aberrant periph-
eral T cells, which correlates with the age of the mice, indi-
cates that Jak3 protein is constitutively required to maintain
a normal population of resting T cells. In total, nine Jak32/2
(tgthy) mice and eleven Jak32/2 (tgthy1spl) mice have been
analyzed; in all cases, the peripheral T cells from the Jak32/2
(tgthy1spl) mice resembled wild-type T cells, whereas the
peripheral T cells from the Jak32/2 (tgthy) mice had a sur-
face phenotype that roughly correlated with the age of the
mice. However, some variation in the precise age at which
the vast majority of Jak32/2 (tgthy) peripheral T cells ac-
quired the Jak32/2 surface phenotype was observed, most
likely owing to variations in the loss of Jak3 protein from
Figure 3. Splenic CD41 T
cells from Jak32/2 (tgthy) mice
acquire increasing numbers of
phenotypically activated T cells
as the mice age. Splenocytes
from  Jak31/2,  Jak32/2,  Jak32/2
(tgthy1spl), Jak32/2 (tgkd), and
three  Jak32/2 (tgthy) mice of dif-
ferent ages were stained with an-
tibodies to CD4, CD8, and
CD44 or CD62L (MEL-14).
The staining of CD44 (top) and
CD62L (bottom) on gated
CD41 T cells is shown on a log-
arithmic scale of fluorescence in-
tensity. All histograms are di-
rectly comparable except the
staining of the 25-d-old Jak32/2
(tgthy) mouse, which was per-
formed with a different lot of
streptavidin-FITC, resulting in a
brighter overall level of CD44
and CD62L fluorescence. Data
shown are representative of
greater than six independent ex-
periments.202 Peripheral Expression of Jak3 Maintains T Cell Function
these cells. Overall, a comparable pattern of activation
marker expression is observed on splenic CD81 T cells in
all mice analyzed (data not shown).
To address whether expression of the wild-type or ki-
nase-dead Jak3 transgenes had reconstituted the function of
Jak32/2 T cells, thymocytes and splenic T cells from the
Jak32/2 (tgthy1spl), the Jak32/2 (tgthy), and the Jak32/2 (tgkd)
mice were assessed for proliferation and cytokine produc-
tion in response to TCR and CD28 costimulation. A set of
data, representative of a total of nine independent experi-
ments performed with different sets of mice, is shown in
Fig. 4. Jak32/2 thymocytes are substantially reduced in
their proliferative response to CD3 plus CD28 stimulation.
As expected, thymocytes from both lines reconstituted
with wild type Jak3, but not with kinase-dead Jak3, have
restored proliferative capacity (Fig. 4, A and B). The in-
complete reconstitution of proliferative capacity with wild
type Jak3 most likely results from the failure of the trans-
genes to be induced following activation. The massive in-
duction of the endogenous Jak3 gene observed after T cell
activation (44) may be essential to sustain a vigorous prolif-
erative response. To test the thymocytes for their cytokine
secretion responses, supernatants from anti-CD3 plus anti-
CD28-stimulated thymocytes were harvested and assayed
for the presence of IL-2 and IL-3. Jak32/2 thymocytes
make substantially less IL-2 and IL-3 than the control
(Jak31/2 ) thymocytes (Fig. 4). As expected, thymocytes
from both Jak32/2 (tgthy1spl) and Jak32/2 (tgthy) mice (Fig.
4 A), but not the Jak32/2 (thykd) mice (Fig. 4 B), are re-
stored in their ability to produce IL-2 and IL-3 in response
to stimulation. These data demonstrate that expression of
wild type Jak3 in thymocytes restores the functional capac-
ity of Jak32/2 cells to secrete cytokines when stimulated.
Splenic T cells from the reconstituted Jak32/2 mice were
Figure 4. Functional responses of Jak32/2 (tgthy) T cells are restored in the thymus, but lost in the periphery. (A) Thymocytes and splenocytes from
Jak31/2, Jak32/2, Jak32/2 (tgthy1spl), and Jak32/2 (tgthy) mice were analyzed for proliferation (top) and IL-2 (middle) or IL-3 (bottom) secretion in re-
sponse to stimulation with anti-CD3 plus anti-CD28 antibodies. All data shown are from one 35-d-old Jak32/2 (tgthy1spl) mouse and one 35-d-old Jak32/2
(tgthy) mouse (designated B). IL-2 secretion data from splenocytes of two additional Jak32/2 (tgthy) mice, one 25 d of age (designated A) and one 42 d of
age (designated C), are also shown. All values are mean 6 SD. Overall, no statistically significant differences between Jak31/2, Jak32/2 (tgthy1spl), and
Jak32/2 (tgthy) thymocytes were observed for IL-2 or IL-3 secretion responses. (B) Thymocytes and splenocytes from Jak31/2, Jak32/2, and Jak32/2 (tgkd)
mice were stimulated with antibodies to CD3 plus CD28. Proliferative, IL-2 secretion, and IL-3 secretion responses are shown. All values are mean 6 SD.
For proliferation assays, all cell populations cultured in media alone gave responses of ,500 cpm. For cytokine assays, cells cultured in media alone se-
creted undetectable levels of IL-2 (,0.02 U/ml) and IL-3 (,0.01 U/ml). Data are representative of 2–9 independent experiments.203 Thomis and Berg
also assessed for their ability to respond to TCR plus CD28
stimulation. Proliferative responses of Jak32/2 splenic T cells
are virtually absent compared with Jak31/2 control cells; in
addition, IL-2 secretion by Jak32/2 T cells is also substan-
tially reduced (Fig. 4, A and B). T cells from Jak32/2 (tgkd)
mice are indistinguishable from Jak32/2 cells for both pro-
liferative and cytokine secretion responses (Fig. 4 B). The
splenic T cells from both the Jak32/2 (tgthy1spl) mice and
the Jak32/2 (tgthy) mice have a limited capacity to prolifer-
ate in response to TCR plus CD28 stimulation (Fig. 4 A).
Most likely, this is due to the fact that maximal proliferative
responses depend on both the initial level of Jak3 protein,
as well as the amount of Jak3 protein that can be induced af-
ter stimulation. Accordingly, we find that proliferative re-
sponses in the two transgenic lines are not consistent be-
tween experiments, and do not correlate well with the
observed levels of Jak3 protein in resting peripheral T cells.
Thus, we include these proliferative responses to demon-
strate that reconstituting Jak3 expression does restore some
proliferative capacity to the Jak32/2 cells, even though quan-
titative conclusions from these data are not possible.
As expected, reconstitution of the Jak32/2 mice with the
(tgthy1spl) transgene restored normal IL-2 secretion from
stimulated splenic T cells (Fig. 4 A). In contrast, IL-2 secre-
tion by the Jak32/2 (tgthy) splenic T cells varied between
individuals, and correlated with the surface phenotype of
the T cells (see Fig. 3). In the Jak32/2 (tgthy) mouse in
which the vast majority of cells resembled normal resting
T cells, IL-2 secretion was normal (Fig. 4, 2/2tgthy-A). In
comparison, splenic T cells from a Jak32/2 (tgthy) mouse in
which z40–50% of the splenic T cells were CD44hi and
CD62Llo, secreted substantially less IL-2 when stimulated
(Fig. 4, 2/2tgthy-B). Finally, in a Jak32/2 (tgthy) mouse in
which the vast majority of cells were CD44hi and CD62Llo,
splenic T cells were severely defective in secreting IL-2
(Fig. 4, 2/2tgthy-C). Analysis of IL-3 secretion supports
these basic conclusions (Fig. 4). These data indicate that
sustained Jak3 expression is required in peripheral T cells to
maintain the resting surface phenotype and T cell function.
The above data suggested that the loss of Jak3 protein
from peripheral T cells of Jak32/2 (tgthy) mice results in the
gradual increase of phenotypically activated CD41 T cells
and the reduced capacity of these cells to synthesize cyto-
kines when stimulated. To test whether the loss of cytokine
production was associated with the change in activation
marker surface expression, we assessed the functional capa-
bility of CD44lo and CD44hi CD41 T cells separately. For
these experiments, T cells were stimulated with anti-CD3
plus anti-CD28 for 5 h and the cytoplasmic IL-2 levels of
CD44lo and CD44hi CD41 T cells were measured by flow
cytometry. This substantially shorter assay for IL-2 produc-
tion also addresses the possibility that the decreased cyto-
kine secretion we observed from stimulated Jak32/2, Jak32/2
(tgthy), and Jak32/2 (tgkd) peripheral T cells might result
from increased apoptosis of these cells compared with
Jak31/2 T cells over the course of the usual 24-h stimula-
tion period. As shown in Fig. 5, 19.0% of CD44lo and
11.0% of CD44hi CD41 splenic T cells from the Jak31/2
Figure 5. Functional deficien-
cies of Jak32/2 and Jak32/2
(tgthy) T cells are confirmed by
intracytoplasmic IL-2 staining.
Splenocytes from a Jak31/2, a
Jak32/2, and three Jak32/2 (tgthy)
mice were cultured for 5 h in
medium alone or with anti-CD3
plus anti-CD28 antibodies. Cells
were harvested, stained with an-
tibodies to CD4, CD44, and
IL-2. CD44 staining on freshly
gated CD41 cells is shown at left;
dot plots of IL-2 versus CD44
staining of gated CD41 cells cul-
tured in either medium alone or
stimulated with CD3 plus CD28
are shown at right. CD44 stain-
ings are shown on a logarithmic
scale of fluorescence intensity;
IL-2 staining is shown on a linear
scale. Data are representative of
three independent experiments.204 Peripheral Expression of Jak3 Maintains T Cell Function
mouse had detectable levels of intracytoplasmic IL-2 after 5 h
of stimulation. In contrast, CD3 plus CD28 stimulation did
not result in any significant IL-2 production by CD44lo
T cells from Jak32/2 mice, whereas 2.9% of CD44hi T cells
stained positive for intracellular IL-2. The IL-2 profiles of
stimulated CD41 T cells from three different Jak32/2 (tgthy)
mice demonstrated that the percentage of IL-21 cells de-
creases as the number of phenotypically activated CD44hi
T cells increases. These data support the conclusion that
peripheral T cells in Jak32/2 (tgthy) mice acquire the acti-
vated surface phenotype and lose responsiveness in parallel,
and that the functional defects in these cells are not due to
increased apoptosis.
These studies of Jak32/2 mice expressing wild-type or
kinase-dead Jak3 from the Lck proximal promoter have
demonstrated several important features about the role of
Jak3 in T cell maturation and function. First, the failure of
the kinase-dead Jak3 gene to reconstitute any of the T cell
defects in the Jak32/2 mice indicates that Jak3 kinase activ-
ity is essential for all the functions of Jak3 assessed in these
experiments. For instance, the small thymus size in the
Jak32/2 mice is presumed to result from the absence of IL-7
receptor signaling (4, 5). As the kinase-dead Jak3 protein is
likely to be fully functional in binding to gc (45, 46), the
phosphorylation of Jak3 by Jak1 in response to IL-7 bind-
ing might have been hypothesized to restore partial func-
tion to the IL-7 receptor. A similar situation might also
have occurred in mature thymocytes or peripheral T cells
in response to IL-2 binding. Yet no thymocyte expansion
in vivo, or T cell proliferation in response to TCR stimula-
tion in vitro, was observed in tgkd-reconstituted Jak32/2
mice. This requirement for Jak3 kinase activity is in direct
contrast with the ability of kinase-dead Jak1 to reconstitute
IFN-g-inducible gene expression in Jak12 cells (47).
Second, the simultaneous reconstitution of normal num-
bers of ab TCR1 thymocytes, gd TCR1 thymocytes, and
NK cells indicates that the Lck proximal promoter is active
in these three lineages of lymphocytes or in a common pre-
cursor to these three cell types. Because we failed to recon-
stitute B cell development in the bone marrow in these
mice, we conclude that the wild-type Jak3 transgenes are
not expressed in a bone marrow progenitor cell that gives
rise to both B and T lymphocytes. Therefore, these data
substantiate a close lineage relationship between T lympho-
cytes and NK cells (48, 49), and suggest the existence of a
common ab T cell–gd T cell–NK cell progenitor that can-
not give rise to B lymphocytes. We do not know whether
the expression of the Lck promoter–driven Jak3 genes ini-
tiates in the thymus, or in an earlier bone marrow–derived
progenitor cell, as we cannot detect any expression of the
Jak3 transgenes in bone marrow (data not shown).
The tgthy-reconstituted Jak32/2 mice provide a system
for distinguishing the roles of Jak3 during T cell develop-
ment from Jak3 function in peripheral T cells. The normal
level of Jak3 expression in thymocytes from these mice cor-
rects virtually all the detectable defects of Jak32/2 thymo-
cytes. In Jak32/2 (tgthy) mice of all ages, thymocyte num-
bers are increased to normal, the production of peripheral
CD41 and CD81 T cells is restored to normal, and cyto-
kine secretion by thymocytes in response to stimulation is
restored. Nonetheless, peripheral T cells in these tgthy-
reconstituted  Jak32/2 mice slowly acquire all the defects of
Jak32/2 T cells. Although the precise kinetics of this effect
vary between individual animals, the Jak32/2 (tgthy) splenic
T cells eventually become phenotypically and functionally
deficient in an identical manner to the Jak32/2 T cells; in
all mice analyzed this process appears complete by 5–6 wk
of age. These results demonstrate that the maintenance of
normal levels of Jak3 protein in mature peripheral T cells
is essential to preserve the continued function of these cells.
This requirement is met in the tgthy1spl-reconstituted Jak32/2
mice, which retain normal T cell phenotype and function
at all ages analyzed.
In addition to the disappearance of proliferative ability,
the loss of Jak3 protein in peripheral T cells leads to the
acquisition of a memory cell phenotype and the loss of
cytokine secretion capacity. Interestingly, this phenotype
strongly resembles that observed in patients with a mod-
erate combined immunodeficiency disease (XCID). The
XCID defect is a point mutation in the cytoplasmic tail of
gc that diminishes, but does not abolish, Jak3 binding (45).
XCID patients have substantial numbers of T cells, but
those T cells are deficient in proliferative responses, have an
activated/memory phenotype, and are impaired in IL-2 se-
cretion after stimulation (50). Thus, individuals with an
impaired Jak3–gc interaction have sufficient Jak3 function
to generate T cells in the thymus, unlike the SCID patients
completely lacking Jak3 or gc expression; yet the peripheral
phenotype of these T cells mimics that seen in our Jak32/2
mice reconstituted with the tgthy transgene.
Currently, we have not yet identified the biochemical
mechanism responsible for the aquisition of a memory cell
phenotype and the loss of cytokine secretion capacity by
the Jak32/2 (tgthy) peripheral T cells. One possible mecha-
nism is suggested by the studies of Nakajima et al. using gc
2
mice (51). Their studies indicate that the mutant T cells
may be receiving activation signals from self- or environ-
mental antigens; owing to their loss of IL-2 receptor signal-
ing, the T cells then may be driven into a state of anergy in
response to these activation events (52, 53). However, our
intracellular IL-2 staining data indicate that even phenotyp-
ically naive T cells lose the capacity to secrete IL-2 when
they lose Jak3 expression. This impaired ability of pheno-
typically normal Jak3-deficient cells to secrete cytokines
when stimulated also suggests the possibility of a previously
unsuspected role for Jak3 in TCR or CD28 signaling. In
fact, both of these mechanisms may be involved and may
contribute together to the numerous T cell defects ob-
served in the Jak3-deficient mice.205 Thomis and Berg
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